Evidence map›Paper›PMID 38490853›Full record

Trial reportEuropean urology2024

Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer.

Nicholas G Nickols, Sonny Tsai, Nathanael Kane, Samantha Tran, Leila Ghayouri, Silvia Diaz-Perez, May Thein, Nancy Anderson-Berman, Jeanie Eason, Amar U Kishan and 19 more

Open access · greenAbstract readLetterClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 21 citations in OpenAlex.

  1. Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 6 institutions in 1 country.

Nicholas G NickolsVA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address: nicholas.nickols@va.gov.
Sonny TsaiVA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
Nathanael KaneVA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Samantha TranVA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
Leila GhayouriVA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
Silvia Diaz-PerezVA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
May TheinVA Long Beach Healthcare System, Long Beach, CA, USA.
Nancy Anderson-BermanVA Long Beach Healthcare System, Long Beach, CA, USA.
Jeanie EasonHunter Holmes McGuire VA Medical Center, Richmond, VA, USA.
Amar U KishanDepartment of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Michael L SteinbergDepartment of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Robert E ReiterDepartment of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Steve P LeeVA Long Beach Healthcare System, Long Beach, CA, USA.
Greg E GinVA Long Beach Healthcare System, Long Beach, CA, USA.
Robert KwonVA Long Beach Healthcare System, Long Beach, CA, USA.
Michael G ChangHunter Holmes McGuire VA Medical Center, Richmond, VA, USA.
Hann-Hsiang ChaoHunter Holmes McGuire VA Medical Center, Richmond, VA, USA.
Abhiskek A SolankiDepartment of Radiation Oncology, Loyola University and Hines VA Medical Center, Chicago, IL, USA.
Rachael SextonCancer Research and Biostatistics, Seattle, WA, USA.
Michael LewisVA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
William LorentzVA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Michael K CheungVA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Diana L GageVA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Sai DurisetiVA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Luca ValleVA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Gholam BerenjiVA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
William J AronsonVA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Isla P GarrawayVA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Matthew B RettigVA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
VA Greater Los Angeles Healthcare System · USVA Long Beach Healthcare System · USUniversity of California, Los Angeles · USHunter Holmes McGuire VA Medical Center · USCancer Research And Biostatistics · USLoyola University Medical Center · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Mechanisms of Prostate Cancer MetastasisR01CA271750 · NCI · CEDARS-SINAI MEDICAL CENTER · PI FREEMAN, MICHAEL R., GARRAWAY, ISLA PEARL · 2021 to 2025
$2.2M
Validation of a microRNA panel to pre-symptomatically predict the risk of radiation-induced fibrosisU01AI189450 · NIAID · CHROMOLOGIC, LLC · PI Diana Lin Gage, Claude J. Rogers · 2025 to 2026
$1.1M
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate CancerI01CX001575 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI NICKOLS, NICHOLAS GEORGE · 2018 to 2023
–
CSRD VA I01 CX001575NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA271750NIAID NIH HHS U01 AI189450
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Neoplasm MetastasisProstatic NeoplasmsHumansMale

Identifiers

PMID38490853
PMCPMC12363338
OpenAlexW4392821374

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.